Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights : Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy

Read MoreHide Full Article

For Immediate Release

Chicago, IL – March 14, 2022 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Company (LLY - Free Report) , Nike, Inc. (NKE - Free Report) , Micron Technology Inc. (MU - Free Report) , Bayer Aktiengesellschaft (BAYRY - Free Report) , and Valero Energy Corp. (VLO - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Analyst Reports for Eli Lilly, Nike and Micron Technologies

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, Nike Inc., and Micron Technology, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Shares of Eli Lilly have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+29.6% vs. +19.2%). Lilly boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. The Zacks analyst believes that Lilly's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others.

It is regularly adding promising new pipeline assets through business development deals. It has an exciting pipeline of potential new medicines including tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both candidates have multibillion dollar sales potential.

However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Nike shares have declined -10.2% over the past year against the Zacks Shoes and Retail Apparel industry's decline of -10.4%. The Zacks analyst believes that Nike's shares have declined in the past year on headwinds related to supply chain constraints. Declines in Greater China and APLA, and the ongoing impacts of supply chain headwinds in the marketplace partly hurt the company's revenues in second-quarter fiscal 2022.

Nike expects volatility in fiscal 2022 due to disruptions caused by the COVID-variants. However, the company's product innovation, brand strength and scale of operations should continue to drive digital sales. It remains on track to deliver on its fiscal 2025 outlook.

(You can read the full research report on NIKE here >>>)

Shares of Micron have underperformed the S&P 500 index in the year-to-date period (-18.7% vs. -10.5%). The Zacks analyst believes that Micron's near-term profitability is likely to be hurt by its planned salary hikes. Additionally, higher levels of customer inventory in the cloud, graphics and enterprise market is a key threat. Soft server demand from several enterprise original equipment manufacturer (OEM) customers is also a concern.

However, Micron has already witnessed growing demand for memory chips from cloud-computing providers and acceleration in 5G (fifth-generation) cellular network adoptions. Rising mix of high-value solutions, enhancement in customer engagement and improvement in cost structure are growth drivers as well. Further, 5G adoption beyond mobile is likely to spur demand for memory and storage, particularly in Internet of Things (IoT) devices and wireless infrastructure.

(You can read the full research report on Micron here >>>)

Other noteworthy reports we are featuring today include Bayer Aktiengesellschaft, and Valero Energy Corp.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500's +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don't miss your chance to get in...because the sooner you do, the more upside you stand to grab.

See Stocks Now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                               

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in